Hormone replacement therapy (HRT) for the relief of symptoms of estrogen deficiency in postmenopausal (at least 1 year after last period) women
2) Usage and dosage
Before taking this medicine, you should undergo a thorough general examination and gynecological examination.
During long-term use of this drug, control tests are performed every 6 months.
Inside the package is an adhesive plate with the day of the week marked on it.
Peel off the sticker on the plate and stick it on the plate containing the tablets.
At this time, attach it so that the day of the first dose matches the part marked "Start".
For example, if the first dose day is Wednesday, the mark of Wednesday may be attached so that it is in a straight line with the mark of "start". The day of the week is now displayed for each tablet, so at a glance you can see if you have taken the tablet you need to take that day. To take the tablets, always start with the tablet marked “start” and take one tablet a day in the direction of the arrow for 28 days.
You will take the white tablets for the first 16 days, then the pink tablets for the next 12 days.
Take the medicine from the new package the next day without interruption.
Each tablet is taken with adequate water.
Women who are 1 year or older after menopause may start taking it at any time as soon as prescribed.
You can take this medicine at any time of the day. However, once you have chosen a time slot, it is best to continue taking it at that time slot (eg, after breakfast).
If you do not take it at the time of your daily dose, take it within 12 hours.
If you forget to take a dose, take it as soon as possible. Bleeding may occur if not taken for several days. Bleeding usually occurs within a few days before the last dose or within the first week of taking the next pack of medicine.
1) pediatric
This medicine is not for use in children and adolescents.
2) Elderly people
There are no studies to suggest the need for dose adjustment in the elderly.
3) Patients with hepatic impairment
This drug has not been specifically studied in patients with hepatic impairment. This medicine is not for use in women with or with a history of liver tumors and in women with severe liver disease. (Refer to section 2. Do not administer to the following patients.) Close observation is required for women with liver dysfunction, and if liver function indicators worsen, use of hormone replacement therapy should be discontinued. (See Section 5. General Precautions)
4) Patients with renal impairment
This drug has not been specifically studied in patients with renal impairment.
